Ex vivo permeation of carprofen from nanoparticles: A comprehensive study through human, porcine and bovine skin as anti-inflammatory agent

International Journal of Pharmaceutics
Alexander ParraAna C Calpena

Abstract

The purpose of this study was the development of poly(d,l-lactide-co-glycolide) acid (PLGA) nanoparticles (NPs) for the dermal delivery of carprofen (CP). The developed nanovehicle was then lyophilized using hydroxypropyl-β-cyclodextrin (HPβCD) as cryoprotectant. The ex vivo permeation profiles were evaluated using Franz diffusion cells using three different types of skin membranes: human, porcine and bovine. Furthermore, biomechanical properties of skin (trans-epidermal water loss and skin hydration) were tested. Finally, the in vivo skin irritation and the anti-inflammatory efficacy were also assayed. Results demonstrated the achievement of NPs 187.32 nm sized with homogeneous distribution, negatively charged surface (-23.39 mV) and high CP entrapment efficiency (75.38%). Permeation studies showed similar diffusion values between human and porcine skins and higher for bovine. No signs of skin irritation were observed in rabbits. Topically applied NPs significantly decreased in vivo inflammation compared to the reference drug in a TPA-induced mouse ear edema model. Thus, it was concluded that NPs containing CP may be a useful tool for the dermal treatment of local inflammation.

References

Apr 22, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·M MássonE Stefánsson
Mar 4, 2000·International Journal of Pharmaceutics·C S MaiaM Schäfer-Korting
Jun 14, 2000·International Journal of Pharmaceutics·R F LopezM V Bentley
Aug 8, 2001·International Journal of Pharmaceutics·T Loftsson, M Masson
Aug 14, 2001·Advanced Drug Delivery Reviews·B M MagnussonM S Roberts
Oct 16, 2003·International Journal of Pharmaceutics·M SametiC-M Lehr
May 8, 2004·International Journal of Pharmaceutics·R J Babu, J K Pandit
Aug 20, 2004·Pharmacological Reviews·Daniel L SimmonsTimothy Hla
Sep 29, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·S Narasimha MurthySek Wen Hui
Oct 27, 2004·Journal of Veterinary Pharmacology and Therapeutics·B Elitok, O M Elitok
Apr 20, 2006·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Wassim AbdelwahedHatem Fessi
May 9, 2006·Skin Pharmacology and Physiology·J LuengoU F Schaefer
Sep 25, 2007·Advanced Drug Delivery Reviews·Biana Godin, Elka Touitou
Oct 23, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·J StahlM Kietzmann
Oct 24, 2008·The British Journal of Dermatology·A C KerrR S Dawe
Mar 5, 2009·Drug Development and Industrial Pharmacy·Jing-Ying ZhangZhong-Gui He
Apr 7, 2009·The Veterinary Record·R O SandersonJ F Innes
May 12, 2009·International Journal of Pharmaceutics·Qingzhi LvGuangxi Zhai
Sep 26, 2013·International Journal of Pharmaceutics·Avnish PatelMajella E Lane
Jan 1, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Mary Lynn McPherson, Nina M Cimino
Jan 28, 2014·Colloids and Surfaces. B, Biointerfaces·Valeri Domínguez-VillegasMaria Luisa Garduño-Ramírez
Feb 4, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·A S RaberC-M Lehr
Mar 20, 2014·Archives of Pharmacal Research·Heui Kyoung ChoIn Woo Cheong
May 13, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sonia AmoresJacinto Lauroba
Jun 24, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amit BadihiSimon Benita
Mar 10, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gøril Eide FlatenNataša Škalko-Basnet

❮ Previous
Next ❯

Citations

Oct 28, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Selenia TernulloNataša Škalko-Basnet
Jul 10, 2017·Skin Pharmacology and Physiology·Luís V RoqueCatarina P Reis
Nov 29, 2017·International Journal of Molecular Sciences·Marcelle Silva-AbreuAna Cristina Calpena
Jun 10, 2017·AAPS PharmSciTech·Thaisa Baccarin, Elenara Lemos-Senna
Nov 12, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sevgi Güngör, Emine Kahraman
Jan 23, 2021·Nanomedicine·Paola Bustos-SalgadoMaría Luisa Garduño-Ramírez
Feb 16, 2021·Nanomedicine·Mireia MallandrichFrancisco Fernández-Campos
Mar 7, 2021·Biomolecules·Gustavo Marinho MirandaJaime Ribeiro-Filho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.